NEW YORK--(BUSINESS WIRE)--Pluristem
Therapeutics Inc. (Nasdaq:
PSTI
-
News)(DAX:PJT), a bio-therapeutics company
dedicated to the commercialization of
unrelated donor-patient (allogeneic) cell therapy products for a variety of degenerative, ischemic
and autoimmune indications, announced today that
Zami Aberman, President & CEO of the Company,
will present at the bioLOGIC Europe 2008
conference on Tuesday, September 16, 2008 at
11:15 a.m. Central European Time at the Crowne
Plaza Hotel, Geneva, Switzerland.
The title of Mr. Aberman’s
presentation is: "Challenges for small and
medium biotechs in bringing biological cell
therapy products to market". The presentation
will include Pluristem Therapeutics’
strategic direction, market positioning, updates
on clinical trials and new studies regarding the
potential of its PLX (PLacental eXpanded) cells.
Mr. Abermam will update on recently obtained
results of PLX-PAD pre-clinical efficacy studies
showing impressive new vessel formation,
indicating that PLX-PAD may bring hope to
millions of people suffering from complications
of diabetes, Buerger's Disease and smoking where
insufficient blood flow to their lower legs
places them at risk of amputation.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a
bio-therapeutics company dedicated to the
commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of
several severe degenerative, ischemic and
autoimmune disorders. The Company is developing
a pipeline of products, stored ready-to-use,
that are derived from human placenta, a
non-controversial, non-embryonic, adult stem
cell source.
These placental adherent stromal cells (ASCs)
are expanded in the Company's proprietary PluriXTM
3D bioreactor, which imitates the natural
microstructure of bone marrow and does not
require supplemental growth factors or other
exogenous materials. Pluristem believes that the
resultant PLX (PLacental eXpanded) cells’
efficacy may be related to the secretion of
cytokines or other potent immune modulators.
Furthermore, PLX cells are immune privileged and
possess immunomodulatory properties, thus
protecting the recipient from immunological
reactions that often accompany transplantations.
Pluristem's first product in development,
PLX-PAD, is intended to improve the quality of
life of millions of people suffering from
peripheral artery disease (PAD). The Company's
products in development also include PLX-IBD,
targeting Inflammatory Bowel Disease (IBD);
PLX-MS, targeting Multiple Sclerosis; PLX-BMT,
targeting the global shortfall of matched tissue
for bone marrow transplantation (BMT) by
improving the engraftment of hematopoietic stem
cells (HSCs) contained in umbilical cord blood;
and PLX-STROKE, targeting ischemic stroke.
Pluristem has offices in the USA with
research and manufacturing facilities in Israel.
See our product animation on YouTube:
http://www.youtube.com/watch?v=QzAANdeg0b0
Safe Harbor Statement
This press release contains forward-looking
statements within the meaning of the "safe
harbor" provisions of the Private Securities
Litigation Reform Act of 1995 and federal
securities laws. For example, when we say that
recently obtained results of PLX-PAD
pre-clinical efficacy studies show impressive
new vessel formation and indicate that PLX-PAD
may bring hope to millions of people suffering
from complications of diabetes, Buerger's
Disease and smoking where insufficient blood
flow to their lower legs places them at risk of
amputation, we are using forward-looking
statements. These forward-looking statements are
based on the current expectations of the
management of Pluristem only, and are subject to
a number of factors and uncertainties that could
cause actual results to differ materially from
those described in the forward-looking
statements. The following factors, among others,
could cause actual results to differ materially
from those described in the forward-looking
statements: failure to obtain required
regulatory approvals, changes in technology and
market requirements; our technology may not be
validated as we progress further and our methods
may not be accepted by the scientific community;
we may be unable to retain or attract key
employees whose knowledge is essential to the
development of our products; unforeseen
scientific difficulties may develop with our
process; results in the laboratory may not
translate to equally good results in real
surgical settings; our patents may not be
sufficient; our products may harm recipients;
changes in legislation; inability to timely
develop and introduce new technologies, products
and applications; loss of market share and
pressure on pricing resulting from competition,
which could cause the actual results or
performance of Pluristem to differ materially
from those contemplated in such forward-looking
statements. Except as otherwise required by law,
Pluristem undertakes no obligation to publicly
release any revisions to these forward-looking
statements to reflect events or circumstances
after the date hereof or to reflect the
occurrence of unanticipated events. For a more
detailed description of the risk and
uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to
time with the Securities and Exchange
Commission.
